Reglagene is developing novel, orally administered medicines designed to fight life threatening brain cancers such as brain metastases from breast and lung cancers and known as high-grade gliomas. Early testing has shown promise in delivering well-tolerated treatment that can cross the blood-brain barrier to deliver effective treatment that may improve patient prospects.
www.reglagene.com
Recent News
MILESTONESSeries A Series A-1 |
TARGET CANCERSBrain Metastases from Breast & Lung Cancers High-Grade Glioma |
FOCUS SECTORTherapies & Management |
WHY WE INVESTED
SERIES A (2021)
We love Reglagene’s global impact potential as a cost-effective disruptor to the brain cancer space. Only four of the 217 FDA-approved cancer medicines are indicated for life-threatening brain cancers. The main reason for the lack of innovation in brain cancer treatment is the extreme difficulty of cancer medicines crossing the blood-brain barrier, a filter that protects the brain from toxins. Reglagene’s lead therapeutic compound is ripe for changing the treatment paradigm for brain cancer patients – it crosses the blood-brain barrier, is orally administered, and is well-tolerated in high doses.
SERIES A-1 (2023)
Since our initial investment in Reglagene’s Series A funding round, we have been impressed by their progress. They completed selection of their lead drug candidate and showed impressive results throughout pre-clinical development. Our Series A-1 investment will help them conduct manufacturing and toxicology studies and progress toward human trials. Their team is impressive and, we believe, on track to contribute a new treatment with the potential to improve the quality and length of survivorship for patients with brain cancers.